Valuation
- Market cap
- 739,000
- Revenue TTM
- $11,510,000
- Net income TTM
- $-53,430,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -464.21%
- Debt to equity
- 0.35
Trading
- Volume
- 471,100
- Avg volume
- 3,032,112
- Day's range
- $0.31 – $0.38
- Shares out
- 1,946,000
- Stochastic %K
- 13%
- Beta
- -0.09
- Analysts
- —
- Price target
- $16.00
Company profile
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription...
Show more
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 415 371 8300
- Website
- https://jaguar.health
- Address
- 200 Pine Street, Suite 400, San Francisco, United States
Latest news
No headlines yet.
Stocktwits
Vextra
Nov 19, 9:05 PM
Look at ticker FGI spiking now. crazy!
If you want to be early for once look at FGI 🚀
FGI is just starting lets hope it pulls a OMH 2,000% type of run!!
FGI on watch from
$JAGX $HCTI $SOUN $BBAI )
0 replies
Bunster
Nov 19, 6:25 PM
$JAGX ANOTHER ALL TIME LOW GIRLS AND BULLS....EV ERY LONG SHARE IN THE UNIVERSE EXCEPT THE DIVIDEND SHARES ARE UNDER WATER. GOOD JOB LISA .wHATS THAT,, THE 20TH 30TH 40TH OR 50TH ALL TIME LOW THIS YEAR???????????????????????
0 replies
Bunster
Nov 19, 3:06 PM
$JAGX WHEN WILL LISA GO TO THE RS IN HER POCKET???????????
1 replies
TimeForChangeNow
Nov 18, 8:44 PM
$JAGX You all should start your own, but if anyone here lost on TNXP sign the petition, you do nothave to donate just skip that and create one to remove LISA https://stkt.co/BcoUDCbT
0 replies
LuckyIrish777
Nov 18, 6:54 PM
$JAGX Alls you have to do is file a complaint with the FBI for fraud and you can get these people locked up. I don’t own any shares so I can’t do it but I feel bad for all the investors.
0 replies
Cheesyisi
Nov 18, 6:50 PM
$JAGX all these paid pumpers by Lisa. How much longer till she sits behind bars for scamming investors?
0 replies